Everything below concerns cjc-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-01. Numbers and descriptions here follow the published literature rather than marketing material.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
=== Infectious diseases === Among the human-specific infectious pathogens studied on humanized mice models, the human immunodeficiency virus has been successfully studied. Besides this, humanized models for studying Ebola virus, Hepatitis B, Hepatitis C, Kaposi's sarcoma-associated herpesvirus, Leishmania major, malaria, and tuberculosis have been reported by various studies. NOD/scid mice models for dengue virus and varicella-zoster virus, and a Rag2null𝛾cnull model for studying influenza virus have also been developed.
In static solution culture, plants are grown in containers of nutrient solution, such as glass Mason jars (typically, in-home applications), pots, buckets, tubs, or tanks. The solution is usually gently aerated but may be un-aerated. If un-aerated, the solution level is kept low enough that enough roots are above the solution so they get adequate oxygen. A hole is cut (or drilled) in the top of the reservoir for each plant; if it is a jar or tub, it may be its lid, but otherwise, cardboard, foil, paper, wood or metal may be put on top. A single reservoir can be dedicated to a single plant, or to various plants. Reservoir size can be increased as plant size increases. A home-made system can be constructed from food containers or glass canning jars with aeration provided by an aquarium pump, aquarium airline tubing, aquarium valves or even a biofilm of green algae on the glass, through photosynthesis. Clear containers can also be covered with aluminium foil, butcher paper, black plastic, or other material to eliminate the effects of negative phototropism. The nutrient solution is changed either on a schedule, such as once per week, or when the concentration drops below a certain level as determined with an electrical conductivity meter. Whenever the solution is depleted below a certain level, either water or fresh nutrient solution is added. A Mariotte's bottle, or a float valve, can be used to automatically maintain the solution level. In raft solution culture, plants are placed in a sheet of buoyant plastic that is floated on the surface of the nutrient solution.
=== Funerary terraces === Two funerary enclosures were discovered north of the voie d'Italie. The northernmost one was destroyed in 1973 to make way for the Centre Bourse. Each rectangular enclosure has an area of approximately 100 m2 (1,100 sq ft). They were in fact terraces intended to be seen from the voie d'Italie. The preserved enclosure is decorated with alternating metopes and triglyphs which rest on a plinth. In the center of this terrace a square-shaped plinth was discovered carved from large white limestone: it might have been the base of an altar or statue. The enclosures were built at the beginning of the 4th century BC. The excavations have revealed several cremations carried out in situ — nineteen in the northern enclosure and six next to the monument with triglyphs. The remains were recovered; they were found in lead, ceramic or bronze urns, which were then placed within stone boxes and arranged in a pit of funerary terraces. Some of these urns are exhibited at the Marseille History Museum. All the tombs date back to the 4th century BC, except for one cremation which might have occurred in the 3rd century BC. At the beginning of the 2nd century, the use of these funerary terraces was abandoned completely and the site covered up with earth.
This stratified squamous epithelium is maintained by cell division within the stratum basale, in which differentiating cells slowly displace outwards through the stratum spinosum to the stratum corneum, where cells are continually shed from the surface. In normal skin, the rate of production equals the rate of loss; about two weeks are needed for a cell to migrate from the basal cell layer to the top of the granular cell layer, and an additional two weeks to cross the stratum corneum. The dermis is the layer of skin between the epidermis and subcutaneous tissue, and comprises two sections, the papillary dermis and the reticular dermis. The superficial papillary dermis interdigitates with the overlying rete ridges of the epidermis, between which the two layers interact through the basement membrane zone. Structural components of the dermis are collagen, elastic fibers, and ground substance. Within these components are the pilosebaceous units, arrector pili muscles, and the eccrine and apocrine glands. The dermis contains two vascular networks that run parallel to the skin surface—one superficial and one deep plexus—which are connected by vertical communicating vessels. The function of blood vessels within the dermis is fourfold: to supply nutrition, to regulate temperature, to modulate inflammation, and to participate in wound healing. The subcutaneous tissue is a layer of fat between the dermis and underlying fascia.
Sources: en.wikipedia.org
== Calculation of Accessible Surface Area == Accessible surface areas is a measure of the solvent exposure of individual atoms or residues (measured in square Angstroms). It corresponds to the surface area of an atom (or residue) that a water molecule can access or touch. In VADAR, the accessible surface areas (ASA) for each residue is presented under two different column headers: RES ASA (residue ASA) and FRAC ASA (fractional ASA). The data listed under the RES ASA column refers to the “residue accessible surface areas” as measured in square Angstroms. The data listed under the FRAC ASA column refers to the fractional residue accessible surface areas (a value ranging from 0 to 1.0). Exposed, exterior, random coil or hydrophilic residues typically have a large fractional accessible surface areas (>0.5), while hydrophobic, beta sheet or interior residues have a small fractional accessible surface areas (<0.2). The fractional accessible surface areas is calculated by dividing a given residue’s observed accessible surface areas by the calculated accessible surface areas for that residue in an extended Gly-Xaa-Gly tripeptide (where Xaa is the residue of interest). VADAR reports accessible surface are values both for the entire amino acid residue and for the amino acid side chains. The accessible surface areas is also calculated for charged atoms (N, O), polar (N, O, S) atoms and for non-polar atoms (C). This information can be used to calculate charged, polar and non-polar surface area.
Helene Langevin is an American medical scientist who served as the Director of the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) between November 2018 and November 2025. She was a professor in the University of Vermont College of Medicine's Department of Neurological Sciences. She is best known for characterizing certain cellular and mechanical effects of acupuncture. She was also a Professor in Residence of Medicine at Harvard Medical School, Brigham and Women's Hospital. Prior to working at NIH, Langevin was the Director of the Osher Center for Integrative Medicine, jointly owned by Brigham and Women's Hospital and Harvard Medical School. Langevin was the principal investigator of studies funded by the National Institutes of Health. The Boston Globe describes her as a "celebrity" in the world of acupuncture.
A very important modification of eukaryotic pre-mRNA is RNA splicing. The majority of eukaryotic pre-mRNAs consist of alternating segments called exons and introns. During the process of splicing, an RNA-protein catalytical complex known as spliceosome catalyzes two transesterification reactions, which remove an intron and release it in form of lariat structure, and then splice neighbouring exons together. In certain cases, some introns or exons can be either removed or retained in mature mRNA. This so-called alternative splicing creates series of different transcripts originating from a single gene. Because these transcripts can be potentially translated into different proteins, splicing extends the complexity of eukaryotic gene expression and the size of a species proteome. Extensive RNA processing may be an evolutionary advantage made possible by the nucleus of eukaryotes. In prokaryotes, transcription and translation happen together, whilst in eukaryotes, the nuclear membrane separates the two processes, giving time for RNA processing to occur.
Diabetic hypoglycemia is a low blood glucose level occurring in a person with diabetes mellitus. It is one of the most common types of hypoglycemia seen in emergency departments and hospitals. According to the National Electronic Injury Surveillance System-All Injury Program (NEISS-AIP), and based on a sample examined between 2004 and 2005, an estimated 55,819 cases (8.0% of total admissions) involved insulin, and severe hypoglycemia is likely the single most common event. In general, hypoglycemia occurs when a treatment to lower the elevated blood glucose of diabetes inaccurately matches the body's physiological need, and therefore causes the glucose to fall to a below-normal level.
Now EC 1.14.14.46, pimeloyl-[acyl-carrier protein] synthase EC 1.14.15.13: pulcherriminic acid synthase EC 1.14.15.14: methyl-branched lipid ω-hydroxylase EC 1.14.15.15: cholestanetriol 26-monooxygenase EC 1.14.15.16: vitamin D3 24-hydroxylase EC 1.14.15.17: pheophorbide a oxygenase EC 1.14.15.18: calcidiol 1-monooxygenase EC 1.14.15.19: C-19 steroid 1α-hydroxylase EC 1.14.15.20: heme oxygenase (biliverdin-producing, ferredoxin) EC 1.14.15.21: zeaxanthin epoxidase EC 1.14.15.22: vitamin D 1,25-hydroxylase EC 1.14.15.23: chloroacetanilide N-alkylformylase EC 1.14.15.24: β-carotene 3-hydroxylase EC 1.14.15.25: p-cymene methyl-monooxygenase EC 1.14.15.26: toluene methyl-monooxygenase EC 1.14.15.27: β-dihydromenaquinone-9 ω-hydroxylase EC 1.14.15.28: cholest-4-en-3-one 26-monooxygenase [(25R)-3-oxocholest-4-en-26-oate forming] EC 1.14.15.29: cholest-4-en-3-one 26-monooxygenase [(25S)-3-oxocholest-4-en-26-oate forming] EC 1.14.15.30: 3-ketosteroid 9α-monooxygenase EC 1.14.15.31: 2-hydroxy-5-methyl-1-naphthoate 7-hydroxylase EC 1.14.15.32: pentalenene oxygenase EC 1.14.15.33: pikromycin synthase EC 1.14.15.34: 20-oxo-5-O-mycaminosyltylactone 23-monooxygenase EC 1.14.15.35: 6-deoxyerythronolide B hydroxylase EC 1.14.15.36: sterol 14α-demethylase (ferredoxin) EC 1.14.15.37: luteothin monooxygenase EC 1.14.15.38: N,N-dimethyl phenylurea N-demethylase EC 1.14.15.39: epi-isozizaene 5-monooxygenase
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.